21 February 2019 11:30
Photo : Rawpixel
A report of the review Board the patented medicine prices indicates that almost all new medicines entering the market in recent years have been associated with costs of treatment are high and that it was specialty drugs such as biologics, orphan and anti-cancer.
The report, ahead of medicines available in the market in 2017, revealed that the number of new drugs launched in Canada generally corresponds to the average of theOrganisation for cooperation and economic development (OECD), but is lower than that of the seven comparator countries of the Council, even if most of them have average prices of patented medicines lowest.
Among the highlights of the report, new medicines are launched from 2009 to 2016 accounted for nearly one-third of the sales of drugs in Canada until 2017.
Orphan drugs, which treat illnesses or rare disorders, accounted for 42 % of new drugs approved in 2016 and 45 % in 2017. This represents a significant increase compared to the average of 33 % from 2009 to 2014 note by the PMPRB.
Cancer treatments represent the largest share of new drugs, accounting for more than a quarter of those approved in 2016 and 2017.
The cost of most drugs introduced in 2016 and 2017 was high, the report said. “The cancer drugs cost an average of 13 700 $ in 28 days of treatment ; and the costs of the treatment of 31 of the 37 drugs other than oncology exceeded $ 10,000 per year,” says the Council.
A delay compared to Europe
The report also showed that Canada lags behind Europe as regards the availability of biosimilar drugs. Canada has approved less than half of the 14 biosimilar drugs approved on the international markets at the end of 2017, the report said. “The prices of biosimilars are often more expensive in Canada and their adoption is relatively modest,” says the Council.
The report is an annual publication that provides information on new drugs entering the canadian and international markets. It examines the availability, sales, consumption, pricing and the costs of the treatment of new drugs approved by the US Food and Drug Administration (FDA), theeuropean medicines Agency and/or Health Canada in 2016 and 2017, and reviews trends since 2009. It also includes a retrospective analysis single of the new biosimilar products approved between 2006 and 2017.